Skip to main content Skip to section navigation Skip to footer
SCYNEXIS, Inc. SCYNEXIS, Inc.
  • About Us
    • Our Mission
    • Leadership
    • Partnerships
    • Careers
    • Contact Us
  • Our Science
    • Ibrexafungerp
    • Life-threatening Infections
    • Community Infections
    • Pipeline
    • Publications and Presentations
  • Our Product
  • News
    • News
    • Events
  • Careers
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Info
    • SEC Filings
    • Governance

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
    • Tear Sheet
  • Financial Info
    • Overview
    • Financial Results
    • Key Ratios
    • Investor Calculator
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Investor Calculator
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
    • Quarterly Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Apr 08, 2025 8:00am EDT

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Mar 12, 2025 5:08pm EDT

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Dec 18, 2024 8:00am EST

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

Nov 06, 2024 4:30pm EST

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 10, 2024 8:00am EDT

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 03, 2024 8:00am EDT

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Aug 27, 2024 8:00am EDT

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 08, 2024 4:30pm EDT

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 23, 2024 7:00am EDT

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

May 08, 2024 4:30pm EDT

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 34
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Scynexis
1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
Facebook Twitter Linkedin
  • Patents
  • Expanded Access
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2025 SCYNEXIS, Inc. All Rights Reserved.